Indications for MEGACE ES:
Anorexia, cachexia, or unexplained significant weight loss in patients diagnosed with AIDS.
Limitations of Use:
Should only be instituted after treatable causes of weight loss are sought and addressed. Not for prophylactic use to avoid weight loss.
625mg/5mL per day.
Do not substitute with other megestrol suspensions (not interchangeable). History of thromboembolic disease. Monitor for signs/symptoms of adrenal insufficiency; consider empiric therapy if occurs. Diabetes. Renal impairment. Elderly. Fetal toxicity. Obtain (–) pregnancy test prior to initiation. Advise females of reproductive potential to use effective contraception during therapy. Nursing mothers: not recommended.
May increase insulin requirements. Decreases indinavir levels.
Nausea, diarrhea, impotence, rash, flatulence, hypertension, asthenia; rare: adrenal insufficiency, breakthrough bleeding.
Concentrated susp (125mg/mL)—5oz